Hetlioz
Authorised
This medicine is authorised for use in the European Union
tasimelteon
MedicineHumanAuthorised
Overview
This is a summary of the European public assessment report (EPAR) for Hetlioz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Hetlioz.
For practical information about using Hetlioz, patients should read the package leaflet or contact their doctor or pharmacist.
Hetlioz is a medicine used to treat totally blind adults with non-24-hour sleep-wake disorder. Non-24-hour sleep-wake disorder is a condition that occurs almost exclusively in people who are completely blind, where patients have sleep patterns that are not synchronised with day and night and often follow a cycle that is longer than the standard 24-hour clock. As a result, patients fall asleep and wake up at unusual times.
Hetlioz contains the active substance tasimelteon.
Because the number of patients with non-24-hour sleep-wake disorder is low, the disease is considered ‘rare’, and Hetlioz was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2011.
Hetlioz is available as 20 mg capsules and can only be obtained with a prescription.
Hetlioz is intended for long-term use. The recommended dose is one capsule per day, taken one hour before bedtime, at the same time every night. The medicine should be taken without food.
A hormone called melatonin plays a key role in co-ordinating the body’s sleep-wake cycle. In people with normal perception of light and dark, melatonin is produced in hours of darkness and promotes sleep by acting on melatonin receptors in specific areas of the brain. The active substance in Hetlioz, tasimelteon, acts on the same receptors as melatonin to promote sleep and regulate sleep patterns. By taking it at a suitable time each day it can help to reset the sleep-wake cycle to more standard timing.
Hetlioz has been shown to be effective at helping patients adjust to the standard 24-hour clock in 2 main studies.
The first study, which involved a total of 84 totally blind patients with non-24-hour sleep-wake disorder, compared Hetlioz with placebo (a dummy treatment). The main measure of effectiveness was the percentage of patients who were able to adjust to the 24-hour clock, which was calculated by looking at how the amount of melatonin breakdown products changed in the patient’s urine over time. 20% of patients who received Hetlioz (8 out of 40) were able to adjust to the 24-hour clock after 1 months of treatment, compared with around 3% of patients on placebo (1 out of 38). Improved results were seen in a subset of patients after 7 months of treatment, which indicate that patients may take weeks or months to respond.
In the second study, 57 patients first received Hetlioz for around 11 weeks. Those patients who were able to adjust to the 24-hour clock (20 patients in total) were then given Hetlioz or placebo for a further 8 weeks to study how well the effect of Hetlioz was maintained. Of the 10 patients who remained on Hetlioz, 9 people remained adjusted to 24-hour clock at the end of the study, compared with 2 of the 10 patients who were switched to placebo.
The most common side effects with Hetlioz (which may affect more than 3 in 100 people) are headache, somnolence, nausea (feeling sick) and dizziness. These are usually mild or moderate in severity and temporary.
For the full list of all side effects and restrictions with Hetlioz, see the package leaflet.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Hetlioz’s benefits are greater than its risks and recommended that it be approved for use in the EU. The CHMP noted that only around 20% of patients would be able to benefit from treatment with Hetlioz, but in view of the lack of approved treatments for non-24-hour sleep-wake disorder, which is a debilitating condition, this modest response was still considered important. However, continued treatment would be necessary to maintain the beneficial effects. Regarding safety, Hetlioz was shown to be well tolerated, causing only few mild side effects.
A risk management plan has been developed to ensure that Hetlioz is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Hetlioz, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the Hetlioz : EPAR - Risk-management-plan summary.
The European Commission granted a marketing authorisation valid throughout the European Union for Hetlioz on 3 July 2015.
For more information about treatment with Hetlioz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information: IAIN/0032/G
10/10/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Hetlioz
- Active substance
- tasimelteon
- International non-proprietary name (INN) or common name
- tasimelteon
- Therapeutic area (MeSH)
- Sleep Disorders, Circadian Rhythm
- Anatomical therapeutic chemical (ATC) code
- N05CH
Pharmacotherapeutic group
PsycholepticsTherapeutic indication
Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.
News on Hetlioz
Topics
This page was last updated on